Epidemiological study of COVID-19 among hospital employees: extension study of the ‘CovidPreventMainz’ (CPM) study (CPMprevac)

Study identification

• EU PAS number:
  EUPAS37174
• Study ID:
  48688
• Official title and acronym:
  Epidemiological study of COVID-19 among hospital employees: extension study of the ‘CovidPreventMainz’ (CPM) study (CPMprevac)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  Given the rapidly changing situation and the urgent need to accelerate the licensing of efficacious candidate vaccines against SARS-CoV-2 infection, this study aims to provide information on the evolution of the epidemiology of COVID-19 in support of a vaccine field efficacy trial. This study aims to describe the epidemiology of COVID-19 in a collective of university hospital employees in order to assess the feasibility of performing a field efficacy trial of CureVac’s investigational SARS-CoV-2-mRNA vaccine (CVnCoV).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Universitätsmedizin der Johannes Gutenberg

UM Mainz

Study timelines

Date when funding contract was signed

Actual:28/08/2020

Study start date

Actual:31/08/2020

Data analysis start date

Planned:01/10/2020

Actual:16/10/2020

Date of interim report, if expected

Planned:05/10/2020

Actual:04/11/2020

Date of final study report

Planned:15/10/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

CureVac AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable